GlassScriptPhysician profile
Matthew K Chatfield
NPI 1720379829
$4,794.51
in general payments reported to CMS, 2019-2025
47 companies · $949 in 2025
The $949 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $745 · 2021: $543 · 2022: $383 · 2023: $712 · 2024: $897 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $414.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $314.34 | 2019-2025 | |
| Abbvie INC. | $311.72 | 2021-2025 | Vraylar |
| Amgen INC. | $308.86 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $296.05 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $219.99 | 2019-2023 | |
| Lilly USA, LLC | $197.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.66 | 2019-2023 | Jardiance |
| Dexcom, INC. | $171.66 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $169.02 | 2019-2025 | Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $146.29 | 2020-2024 | Trintellix |
| Amarin Pharma, INC. | $126.42 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $123.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.33 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $110.03 | 2021-2024 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Chatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.